Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florian Fitzal

Showing results (61-70 of 88) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
The Lancet. Oncology|August 8, 2020
Knowledge gaps in oncoplastic breast surgeryWalter P Weber, Monica Morrow, Jana de Boniface, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Journal of Translational Medicine|October 8, 2024
Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccineViktoria Knöbl, Lukas Maier, Stefan Grasl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
Virchows Archiv : an International Journal of Pathology|May 9, 2020
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimensKristina A Tendl-Schulz, Fabian Rössler, Philipp Wimmer, et al.
The Lancet. Oncology|August 23, 2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyMichael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
The New England Journal of Medicine|February 14, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerMichael Gnant, Brigitte Mlineritsch, Walter Schippinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study GroupPeter C Dubsky, Raimund Jakesz, Brigitte Mlineritsch, et al.
Breast Care (Basel, Switzerland)|June 16, 2022
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)Simon P Gampenrieder, Magdalena Pircher, Christian Fesl, et al.
Pageof 9

Showing results (61-70 of 88) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8Martin Filipits, Margaretha Rudas, Verena Kainz, et al.
The Lancet. Oncology|August 8, 2020
Knowledge gaps in oncoplastic breast surgeryWalter P Weber, Monica Morrow, Jana de Boniface, et al.
The Lancet. Oncology|February 24, 2019
Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trialMichael Gnant, Georg Pfeiler, Günther G Steger, et al.
Journal of Translational Medicine|October 8, 2024
Monocyte subsets in breast cancer patients under treatment with aromatase inhibitor and mucin-1 cancer vaccineViktoria Knöbl, Lukas Maier, Stefan Grasl, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2017
Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast CancerChristian F Singer, Yen Y Tan, Florian Fitzal, et al.
Virchows Archiv : an International Journal of Pathology|May 9, 2020
Factors influencing agreement of breast cancer luminal molecular subtype by Ki67 labeling index between core needle biopsy and surgical resection specimensKristina A Tendl-Schulz, Fabian Rössler, Philipp Wimmer, et al.
The Lancet. Oncology|August 23, 2008
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyMichael Gnant, Brigitte Mlineritsch, Gero Luschin-Ebengreuth, et al.
The New England Journal of Medicine|February 14, 2009
Endocrine therapy plus zoledronic acid in premenopausal breast cancerMichael Gnant, Brigitte Mlineritsch, Walter Schippinger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study GroupPeter C Dubsky, Raimund Jakesz, Brigitte Mlineritsch, et al.
Breast Care (Basel, Switzerland)|June 16, 2022
Influence of Height on Risk and Outcome of Patients with Early Breast Cancer: A Pooled Analysis of 4,925 Patients from 5 Randomized Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)Simon P Gampenrieder, Magdalena Pircher, Christian Fesl, et al.
Pageof 9